The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Mesenchymal stem cell effects on T-cell effector pathways
Open accessAbstract
Mesenchymal stem (stromal) cells (MSCs) are rare, multipotent progenitor cells that can be isolated and expanded from bone marrow and other tissues. Strikingly, MSCs modulate the functions of immune cells, including T cells, B cells, natural killer cells, monocyte/macrophages, dendritic cells, and neutrophils. T cells, activated to perform a range of different effector functions, are the primary mediators of many autoimmune and inflammatory diseases as well as of transplant rejection and graft-versus-host disease. Well-defined T-cell effector phenotypes include the CD4+ (T helper cell) subsets Th1, Th2, and Th17 cells and cytotoxic T lymphocytes derived from antigen-specific activation of naïve CD8+ precursors. In addition, naturally occurring and induced regulatory T cells (Treg) represent CD4+ and CD8+ T-cell phenotypes that potently suppress effector T cells to prevent autoimmunity, maintain self-tolerance, and limit inflammatory tissue injury. Many immune-mediated diseases entail an imbalance between Treg and effector T cells of one or more phenotypes. MSCs broadly suppress T-cell activation and proliferation in vitro via a plethora of soluble and cell contact-dependent mediators. These mediators may act directly upon T cells or indirectly via modulation of antigen-presenting cells and other accessory cells. MSC administration has also been shown to be variably associated with beneficial effects in autoimmune and transplant models as well as in several human clinical trials. In a small number of studies, however, MSC administration has been found to aggravate T cell-mediated tissue injury. The multiple effects of MSCs on cellular immunity may reflect their diverse influences on the different T-cell effector subpopulations and their capacity to specifically protect or induce Treg populations. In this review, we focus on findings from the recent literature in which specific modulatory effects of MSCs on one or more individual effector T-cell subsets and Treg phenotypes have been examined in vitro, in relevant animal models of in vivo immunological disease, and in human subjects. We conclude that MSCs have the potential to directly or indirectly inhibit disease-associated Th1, Th2, and Th17 cells as well as cytotoxic T lymphocytes but that many key questions regarding the potency, specificity, mechanistic basis, and predictable therapeutic value of these modulatory effects remain unanswered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00769-x · Cited by 2,295
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865
Mesenchymal stem cells: clinical applications and biological characterization
Barry, F. P., & Murphy, J. M. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.11.001 · Cited by 1,665
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy
Zappia, E., Casazza, S., Pedemonte, E., Benvenuto, F., Bonanni, I., Gerdoni, E., Giunti, D., Ceravolo, A., Cazzanti, F., Frassoni, F., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1496 · Cited by 1,430
Why are MSCs therapeutic? New data: new insight
Caplan, A. (2009) · The Journal of Pathology · doi:10.1002/path.2469 · Cited by 1,114
English, K., Ryan, J. M., Tobin, L., Murphy, M. J., Barry, F. P., & Mahon, B. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03874.x · Cited by 676
Rasmusson, I., Ringdén, O., Sundberg, B., & Le Blanc, K. (2003) · Transplantation · doi:10.1097/01.tp.0000082540.43730.80 · Cited by 663
Ren, G., Zhao, X., Zhang, L., Zhang, J., L'Huillier, A., Ling, W., Roberts, A. I., Le, A. D., Shi, S., Shao, C., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902023 · Cited by 656
(2008) · Choice Reviews Online · doi:10.5860/choice.45-5565 · Cited by 648
Cited by
Weiss, A. R. R., & Dahlke, M. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01191 · Cited by 695
The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity
Zhou, Y., Yamamoto, Y., Xiao, Z., & Ochiya, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071025 · Cited by 303
Mattar, P., & Bieback, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00560 · Cited by 300
Kobolak, J., Dinnyes, A., Memic, A., Khademhosseini, A., & Mobasheri, A. (2016) · Methods · doi:10.1016/j.ymeth.2015.09.016 · Cited by 273
Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway
Luz-Crawford, P., Noël, D., Fernandez, X., Khoury, M., Figueroa, F., Carrión, F., Jorgensen, C., & Djouad, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045272 · Cited by 195
Metadata
- Authors
- Duffy, M. M., Ritter, T., Ceredig, R., & Griffin, M. D.
- Venue
- Stem Cell Research & Therapy
- Published
- 2011-08
- Volume
- 2
- Issue
- 4
- Pages
- 34-34
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W1967524272
- Cited by
- 430
- References
- 54
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stem cell effects on T-cell effector pathways. https://app.cochat.ai/papers/10.1186/scrt75
- The paper
- Duffy, M. M., Ritter, T., Ceredig, R., & Griffin, M. D. (2011). Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research & Therapy. https://doi.org/10.1186/scrt75
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.